- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- April 2023
- 112 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- November 2023
- 189 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2022
- 153 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Drug Pipelines
- September 2020
- 57 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- November 2023
- 87 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2022
- 46 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2022
- 180 Pages
Global
From €2377EUR$2,500USD£1,997GBP

Pseudomonas Aeruginosa Infection is a type of infection caused by the Gram-negative bacterium Pseudomonas aeruginosa. It is a common cause of hospital-acquired infections, particularly in immunocompromised patients. It is also a major cause of morbidity and mortality in cystic fibrosis patients. Treatment of Pseudomonas Aeruginosa Infection typically involves the use of antibiotics, such as carbapenems, aminoglycosides, and fluoroquinolones. In some cases, combination therapy may be necessary.
Infectious Diseases Drugs are used to treat a wide range of infections, including those caused by Pseudomonas Aeruginosa. These drugs are typically administered orally or intravenously, depending on the severity of the infection. They are designed to target the specific bacteria causing the infection, while minimizing the risk of side effects.
Some companies in the Pseudomonas Aeruginosa Infection market include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more